Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting
June 22, 2022 08:00 ET
|
NextCure
BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at the JMP Securities Life Sciences Conference
June 08, 2022 08:00 ET
|
NextCure
BELTSVILLE, Md., June 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Provides Business Update and Reports First Quarter 2022 Financial Results
May 05, 2022 16:05 ET
|
NextCure
On track to report data from all three clinical programs in the second half of 2022First quarter ending cash of $201.3 million expected to fund operations into the first quarter of 2024 ...
NextCure to Present at the BofA Securities 2022 Healthcare Conference
May 03, 2022 08:00 ET
|
NextCure
BELTSVILLE, Md., May 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation
April 19, 2022 07:30 ET
|
NextCure
BELTSVILLE, Md., April 19, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at 21st Annual Needham Virtual Healthcare Conference
April 05, 2022 08:00 ET
|
NextCure
BELTSVILLE, Md., April 05, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 03, 2022 16:05 ET
|
NextCure
Multiple data readouts expected in 2022, including updates for all three clinical programs Ends 2021 with cash position of $219.6 million that is expected to fund operations into first quarter of...
NextCure to Present at 11th Annual SVB Leerink Global Healthcare Conference
February 08, 2022 08:00 ET
|
NextCure
BELTSVILLE, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting
December 13, 2021 08:05 ET
|
NextCure
BELTSVILLE, Md., Dec. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...
NextCure to Present at The JMP Securities Hematology and Oncology Summit
November 30, 2021 08:00 ET
|
NextCure
BELTSVILLE, Md., Nov. 30, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class...